当前位置:主页 > 医学论文 > 肿瘤论文 >

纳米炭与亚甲蓝在乳腺癌前哨淋巴结活检中的应用

发布时间:2019-06-13 13:58
【摘要】:乳腺癌中国女性最常见的恶性肿瘤,近年来其发病率和死亡率呈明显上升趋势。ALND在乳腺癌的外科治疗中占有重要的地位,但却带来了上肢淋巴水肿、疼痛、麻木及肩关节运动障碍等术后并发症。前哨淋巴结活检SLNB能较为准确地预测腋窝淋巴结状态,使SLN阴性乳腺癌患者免于ALND,减少了手术创伤,提高了患者术后生活质量。SLNB的效果在很大程度上取决于示踪方式以及示踪剂的选择,寻找示踪效果好且安全性高的示踪剂至关重要。目的:评价纳米炭与亚甲蓝作为乳腺癌前哨淋巴结示踪剂的可行性。方法:选择2012年10月~2013年9月在我院住院治疗的女性早期乳腺癌患者共160例,术前均行同位素标记,分两组各80例分别使用亚甲蓝与纳米炭作为示踪剂行术中前哨淋巴结活检,观测并记录同位素法与两种染料法的前哨淋巴结检出情况。结果:亚甲蓝组前哨淋巴结检出率为86.25%(69/80),纳米炭组前哨淋巴结检出率为93.25%(77/80),后者明显高于前者(P0.05),准确率、假阴性率与敏感性两组间差异无统计学意义(均P0.05)。结论:两种染料均可作为前哨淋巴结的安全示踪剂,纳米炭法检出率优于亚甲蓝法。
[Abstract]:The most common malignant tumor in Chinese women with breast cancer has shown an increasing trend in incidence and mortality in recent years. ALND plays an important role in the surgical treatment of breast cancer, but it brings postoperative complications such as upper limb lymphoedema, pain, numbness and shoulder joint motion disorder. Sentinel lymph node biopsies can accurately predict axillary lymph node status, make patients with SLN negative breast cancer free from ALND, and improve the quality of life of patients after operation. The effect of SLNB depends to a large extent on the tracer mode and the choice of tracer, so it is very important to find a tracer with good tracer effect and high safety. Objective: to evaluate the feasibility of nano-carbon and methylene blue as sentinel lymph node tracer for breast cancer. Methods: 160 female patients with early breast cancer who were hospitalized in our hospital from October 2012 to September 2013 were treated with isotopic labeling before operation. 80 patients in each group were treated with methylene blue and carbon nanoparticles as tracers for sentinel lymph node biopsy. the sentinel lymph nodes detected by isotope method and dye method were observed and recorded. Results: the detection rate of sentinel lymph nodes in methylene blue group was 86.25% (69 鈮,

本文编号:2498573

资料下载
论文发表

本文链接:https://www.wllwen.com/yixuelunwen/zlx/2498573.html


Copyright(c)文论论文网All Rights Reserved | 网站地图 |

版权申明:资料由用户a2839***提供,本站仅收录摘要或目录,作者需要删除请E-mail邮箱bigeng88@qq.com